New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Avis Budget Group, Inc. ("Avis Budget Group, Inc.") (NASDAQ: CAR) concerning potential violations of the federal securities laws.The Q4 2025 loss was driven in significant part by a material write-down of the company's electric vehicle fleet. The EV-fleet impairment directly reduced the value of vehicles pledged as collateral for $965 million in asset-backed securities ...

New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Coty Inc. ("Coty Inc.") (NYSE: COTY) concerning potential violations of the federal securities laws.Coty's quarterly loss stands out within the global beauty and personal care sector, an industry that has generally posted resilient consumer demand over the past two years. Peers such as Estée Lauder, L'Oréal, and Shiseido reported stable or improving margins in their mos ...

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Hub Group, Inc. (Nasdaq: HUBG) for potential securities law violations. Investors who have lost money in their Hub Group investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/hubg. What is this all about? Shares of Hub Group fell more than 20% in intraday trading on February 5, 2026, after the company identified an accounting error related to ...

Core Viewpoint - Agilon Health, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its financial guidance and strategic actions [1] Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from February 26, 2025, to August 4, 2025, with a deadline for lead plaintiff appointment on March 2, 2026 [1] - The complaint alleges that Agilon's 2026 guidance was unattainable, which the company was aware of when communicating with investors [1] Group 2: Company Misrepresentation - Agilon is accused of overstating the impact of its "strategic actions" intended to mitigate risk [1] - The lawsuit claims that Agilon's public statements were false and materially misleading throughout the class period [1]

Core Viewpoint - Masonite International Corporation is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its share repurchase activities while in possession of acquisition offers from Owens Corning at higher prices [1]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is from June 5, 2023, to February 8, 2024, with a deadline for participation set for April 7, 2026 [1]. - The complaint alleges that Masonite repurchased shares from investors while having knowledge of acquisition offers that would have significantly increased share prices [1]. Group 2: Investor Information - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this appointment is not necessary to participate in any recovery [1]. - The DJS Law Group specializes in securities class actions and aims to enhance investor returns through advocacy and counseling [1].

Core Viewpoint - Kyndryl Holdings, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its financial performance and internal controls during the class period from August 7, 2024, to February 9, 2026 [1]. Group 1: Lawsuit Details - The lawsuit alleges that Kyndryl's financial statements were misstated throughout the class period, leading to materially misleading public statements [1]. - The deadline for shareholders to participate in the lawsuit is April 13, 2026 [1]. - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments [1]. Group 2: Company Background - Kyndryl Holdings, Inc. is listed on the NYSE under the ticker symbol KD [1]. - The DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [1].

Core Viewpoint - REGENXBIO Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding the safety and efficacy of its RGX-111 product candidate, which led to a clinical hold by the FDA after a participant developed a tumor [1]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is from February 9, 2022, to January 27, 2026, with a deadline for lead plaintiff appointments set for April 14, 2026 [1]. - The complaint alleges that REGENXBIO consistently made positive statements about RGX-111 while concealing adverse safety and efficacy information from investors [1]. Group 2: Impact on Shareholders - Shareholders who purchased RGNX shares during the class period are encouraged to contact the DJS Law Group regarding potential recovery of losses [1]. - The lawsuit highlights the potential financial impact on shareholders due to the misleading public statements made by the company [1].

PayPal Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 20, 2026 to Discuss Your Rights - PYPL [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PayPal Holdings, Inc. (NASDAQ: PYPL).Shareholders who purchased shares of PYPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is no ...

Core Viewpoint - Hub Group, Inc. is under investigation for potential violations of federal securities laws following a significant accounting error that led to a sharp decline in its stock price [1]. Financial Performance - Hub Group reached a 52-week high of $48.96 per share on February 3, 2026, but saw its shares drop to around $37 just three days later, resulting in a loss of approximately $12 per share [2]. - The company's Q4 2025 earnings per share were reported at $0.45, slightly above the consensus estimate of $0.44, and revenue exceeded expectations. However, this positive result was overshadowed by the disclosure of a restatement affecting three prior quarters and an estimated $77 million in understated costs [4]. Analyst Reactions - Following the accounting error announcement, Stifel downgraded Hub Group from Buy to Sell, reducing its price target from $52 to $27, a 48% decrease. Baird also downgraded its rating from Outperform to Neutral, cutting its target from $47 to $29, a 38% reduction [3]. - Both downgrades were issued on February 6, 2026, contributing to increased selling pressure on the stock [3]. Market Impact - The disconnect between the modest earnings beat and the 23% decline in stock price indicates that the market views the accounting issue as significantly more serious than the quarterly results [4].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for securities law violations, specifically for making false and misleading statements regarding its FDA approval process and study design [1] Group 1: Lawsuit Details - The lawsuit pertains to violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from September 24, 2025, to October 31, 2025, with a deadline for lead plaintiff appointments set for April 13, 2026 [1] - The complaint alleges that uniQure's public statements were materially misleading, particularly regarding the likelihood of delays in its Biologics License Application (BLA) with the FDA due to the need for additional studies [1] Group 2: Company Background - uniQure N.V. is a biotechnology company that focuses on gene therapies [1] - The company is listed on NASDAQ under the ticker symbol QURE [1] - The DJS Law Group, which is handling the lawsuit, specializes in securities class actions and corporate governance litigation [1]